Memodyne Official Website › Articles › Evidence

Evidence

What actually moves memory in the published record

By the Memodyne Team at Memoadyne · Published 2026-09-20 · Last updated 2026-09-20 · Reviewed by Dr. Gianna Link, MD, PhD

The question a supplement page usually avoids

If somebody walked into this desk and asked what the best available evidence says about protecting their memory, the honest answer would not start with a capsule. It would start with three bodies of randomised evidence, none of which is sold here, and this article is that answer written down.

Publishing that on a shop is peculiar, and the reasoning behind it is straightforward. A page that flatters its own product teaches the reader to discount everything else on it, and somebody who learns from another source that the strongest evidence lies elsewhere will apply that discount to this whole website, quite rightly.

US POINTER: 2,111 adults, two years

The US POINTER trial is the largest recent randomised test of a lifestyle programme for cognition. It enrolled 2,111 adults aged 60 to 79 at five American sites, all of them sedentary with a suboptimal diet and at least two further risk criteria, and randomised them to a structured or a self-guided two-year programme. Both encouraged physical and cognitive activity, a better diet, social engagement and cardiovascular monitoring; they differed in structure, intensity and accountability.

Global cognition improved in both arms. The structured arm improved faster, by 0.029 standard deviations a year, a statistically significant difference that held for carriers and non-carriers of APOE e4 alike.

Two things are worth noticing. The effect size is modest, which is what real effects in this field look like. And the control arm was not nothing: it was a self-guided version of the same programme, so the trial was measuring the value of structure rather than the value of the activities.

FINGER: the trial POINTER was built from

FINGER came first, in Finland. It enrolled 1,260 adults aged 60 to 77 with an elevated dementia risk score and cognition at or slightly below the expected level for their age, and randomised them to a two-year multidomain intervention of diet, exercise, cognitive training and vascular risk monitoring, or to general health advice.

The intervention group improved more on a comprehensive neuropsychological battery than the control group did. It was the first randomised trial to show that a multidomain programme could affect cognition in an at-risk population, and it is the reason POINTER and its equivalents in other countries exist.

Exercise, and which kind

A 2026 Bayesian network meta-analysis pooled 38 randomised trials in 2,928 adults aged 65 and over and asked a more precise question than most: which type of exercise, and at what dose, improves executive function.

In cognitively healthy older adults, aerobic exercise significantly improved all three executive-function domains, while mind-body training and resistance training did not. In older adults who already had cognitive impairment, all three exercise types improved working memory.

That distinction is useful. It says the answer depends on where you are starting from, and it gives a specific recommendation rather than a general exhortation to be active.

The last row is the product this website sells. Printing it in the same table as the other three is the only honest way to present them.

Where a capsule sits beside all that

There is a thread connecting this bottle to those trials, and it is thinner than the marketing in this category implies. Vascular risk is a modifiable risk factor for cognitive decline; both lifestyle programmes included vascular risk monitoring; and the amino acids in this formula have a small measured effect on blood pressure at gram amounts.

That is a real connection and it is three steps long, with a small amount at the end of it: 400 mg of arginine and 200 mg of citrulline, against trials in grams. A reader who understands that is in a good position to decide whether to buy a capsule. A reader who has been told the capsule is clinically proven for memory is not, and no trial of any product in this category supports that phrase.

Blood pressure: the thread that connects the two

There is one honest link between a bottle of amino acids and the trials described above, and it runs through blood pressure. It is worth following carefully, because it is both real and much weaker than the marketing in this category implies.

Raised blood pressure is an established modifiable risk factor for cognitive decline. Both multidomain programmes above included vascular risk monitoring as one of their components, precisely for that reason. And the amino acids on this label do have a measured effect on blood pressure: about 6 mmHg systolic for arginine at 4 g a day or more, and about 4 mmHg for citrulline in middle-aged and older adults.

So the chain is: capsule, to amino acid, to blood pressure, to vascular risk, to cognition. Four links, each of which loses something, with 600 mg of amino acids at the first one against grams in the trials. That is not nothing, and it is not a memory claim.

What none of this evidence says

An article like this can be misread in two directions, and both misreadings are worth closing off.

• It does not say a lifestyle programme prevents dementia. POINTER measured a difference in the rate of cognitive change between two active programmes over two years, which is a long way short of prevention.
• It does not say supplements do nothing. It says no trial of a finished product in this category exists, which is a statement about the evidence rather than about the capsule.
• It does not say exercise is a treatment. The network meta-analysis measured executive function in trials of varying quality, and its own authors separate healthy older adults from those with existing impairment.
• It does not say a worried reader should do nothing. It says the first step is an assessment rather than a purchase, which is the opposite of doing nothing.

The reason a retail desk publishes this at all is that the alternative is worse. A reader who buys a capsule believing it is the strongest available option has been sold something on a false premise, and will find out. A reader who buys one knowing exactly where it sits has bought what this desk is actually selling.

Further reading

A last word on how to read any of this. The trials above are the strongest evidence available, and they are still trials of programmes rather than of people: an average effect across two thousand participants says what happened to a group over two years, not what will happen to you. That is not a reason to dismiss them, it is the reason they are worth more than a testimonial. A single person's account of a capsule, however sincere, carries none of that structure, which is exactly why the reviews on this website are described as opinion and the trials are described as evidence.

A 2023 review in CNS Drugs surveyed 103 memory supplements on sale in American pharmacies and worked through the evidence for each, which is the best single paper for understanding this shelf. The Alzheimer association page on alternative treatments is the plainest consumer summary. And the memory supplement guide on this site covers the category at length, including the product sold here.